Article
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
The Journal of clinical investigation - 1 Oct 2018
Nava Rodrigues Daniel, Rescigno Pasquale, Liu David, Yuan Wei, Carreira Suzanne, Lambros Maryou B, Seed George, Mateo Joaquin, Riisnaes Ruth, Mullane Stephanie, Margolis Claire, Miao Diana, Miranda Susana, Dolling David, Clarke Matthew, Bertan Claudia, Crespo Mateus, Boysen Gunther, Ferreira Ana, Sharp Adam, Figueiredo Ines, Keliher Daniel, Aldubayan Saud, Burke Kelly P, Sumanasuriya Semini, Fontes Mariane Sousa, Bianchini Diletta, Zafeiriou Zafeiris, Teixeira Mendes Larissa Sena, Mouw Kent, Schweizer Michael T, Pritchard Colin C, Salipante Stephen, Taplin Mary-Ellen, Beltran Himisha, Rubin Mark A, Cieslik Marcin, Robinson Dan, Heath Elizabeth, Schultz Nikolaus, Armenia Joshua, Abida Wassim, Scher Howard, Lord Christopher, D'Andrea Alan, Sawyers Charles L, Chinnaiyan Arul M, Alimonti Andrea, Nelson Peter S, Drake Charles G, Van Allen Eliezer M, de Bono Johann S
Abstract excerpt
BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS: Defective mismatch repair (dMMR) status was determined by either loss of mismatch repair protein expression on IHC or microsatellite instability (MSI) by PCR in 127 APC biopsies from 124 patients (Royal Marsden [RMH] cohort); MSI by targeted panel next-generation...
Read the complete abstract on PubMed